Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 125, Issue 6, Pages 1464-1472Publisher
WILEY
DOI: 10.1002/ijc.24521
Keywords
NF-kappa B; primary effusion lymphoma; cepharanthine; animal model
Categories
Funding
- Ministry of Health, Labour and Welfare of Japan [H19-AIDS-003]
- Ministry of Education, Science, Sports, and Culture of Japan
Ask authors/readers for more resources
Primary effusion lymphoma (PEL) is a unique and recently identified non-Hodgkin's lymphoma that was originally identified in patients with AIDS. PEL is caused by the Kaposi sarcoma-associated herpes virus (KSHV/HHV-8) and shows a peculiar presentation involving liquid growth in the serous body cavity and a poor prognosis. As the nuclear factor (NF)-kappa B pathway is activated in PEL and plays a central role in oncogenesis, we examined the effect of a biscoclaurine alkaloid, cepharanthine (CEP) on PEL derived cell lines (BCBL-1, TY-1 and RM-P1), in vitro and in vivo. An methylthioletrazole assay revealed that the cell proliferation of PEL cell lines was significantly suppressed by the addition of CEP (1-10 mu g/ml). CEP also inhibited NF-kappa B activation and induced apoptotic cell death in PEL cell lines. We established a PEL animal model by intraperitoneal injection of BCBL-1, which led to the development of ascites and diffuse infiltration of organs, without obvious solid lymphoma formation, which resembles the diffuse nature of human PEL. Intraperitoneal administration of CEP inhibited ascites formation and diffuse infiltration of BCBL-1 without significant systemic toxicity in this model. These results indicate that NF-kappa B could be an ideal molecular target for treating PEL and that CEP is quite useful as a unique therapeutic agent for PEL. (C) 2009 UICC
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available